Systemic immune response to a CD40 agonist antibody in nonhuman primates

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• CD40, a receptor on immune cells and some cancer cells, is crucial for immune activation.
• Ligation of CD40 enhances antigen presentation and T cell activation, crucial for anti-tumor immunity.

Purpose of the Study:

• To evaluate the safety and efficacy of CD40 agonistic therapies, specifically selicrelumab, in stimulating immune responses.
• To assess the immunotoxicological effects of subcutaneous selicrelumab administration in cynomolgus macaques.

Main Methods:

• Preclinical studies involving subcutaneous administration of CD40 agonistic antibodies.
• Two independent studies in cynomolgus macaques to evaluate immunotoxicological effects and immune response.

Main Results:

• CD40 agonistic therapies have shown success as single agents in patients with solid tumors and hematologic malignancies.
• Subcutaneous administration reduced systemic toxicity and enhanced localized immune response in preclinical models.
• Monkey studies demonstrated selicrelumab is safe and effective at stimulating systemic immunity at clinical doses via subcutaneous injection.

Conclusions:

• CD40 agonists hold promise for cancer immunotherapy by mediating tumor regression through both T cell-dependent and independent mechanisms.
• Subcutaneous administration of selicrelumab is a safe and effective method for stimulating a systemic immune response, warranting further clinical investigation.